Calcium channel blockers potentiate gemcitabine chemotherapy  in pancreatic cancer

XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer

(2022) Daniel R. Principe et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

(2022) Daniel R. Principe et al.   Frontiers in Oncology

Amlodipine and Verapamil, Voltage-Gated Ca2+ Channel Inhibitors, Suppressed the Growth of Gastric Cancer Stem Cells

(2021) Atsushi Shiozaki et al.   ANNALS OF SURGICAL ONCOLOGY

Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

(2021) Alexandre F. Aissa et al.   Nature Communications

Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin

(2021) Ponmathi Panneerpandian et al.   TOXICOLOGY IN VITRO

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy

(2021) Daniel R. Principe et al.   Frontiers in Oncology

The Role of Calmodulin in Tumor Cell Migration, Invasiveness, and Metastasis

(2020) Antonio Villalobo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis

(2020) Nisha Kanwar et al.   EBioMedicine

Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy

(2020) Daniel R Principe et al.   CANCER RESEARCH

Anticancer Effects of Antihypertensive L-Type Calcium Channel Blockers on Chemoresistant Lung Cancer Cells via Autophagy and Apoptosis

(2020) Bing-Sang Wong et al.   Cancer Management and Research

Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study

(2020) Samuel J. Tingle et al.   ANTI-CANCER DRUGS

LLGL1 Regulates Gemcitabine Resistance by Modulating ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma

(2020) Yin-Xin Zhu et al.   Cellular and Molecular Gastroenterology and Hepatology

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

(2019) Andrea Wang-Gillam et al.   EUROPEAN JOURNAL OF CANCER

KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner

(2019) Constance Agamasu et al.   BIOPHYSICAL JOURNAL

The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin

(2019) Hyunbum Jang et al.   STRUCTURE

Ca2+-Dependent Switch of Calmodulin Interaction Mode with Tandem IQ Motifs in the Scaffolding Protein IQGAP1

(2019) Mingzhen Zhang et al.   BIOCHEMISTRY

Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers

(2018) Ruth Nussinov et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

(2018) Yang Li et al.   Cell Death & Disease

Genetic and transcriptional evolution alters cancer cell line drug response

(2018) Uri Ben-David et al.   NATURE

Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response

(2018) Chae Yoon Lim et al.   PANCREATOLOGY

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer

(2018) Daniel R Principe et al.   MOLECULAR CANCER THERAPEUTICS

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer

(2018) Yanfei Jia et al.   ONCOGENE

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary

(2017) Davendra P.S. Sohal et al.   Journal of Oncology Practice

Regulation of K-Ras4B Membrane Binding by Calmodulin

(2016) Benjamin Sperlich et al.   BIOPHYSICAL JOURNAL

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

(2016) Sangjin Shin et al.   BMC CANCER

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

(2015) Daniel V.T. Catenacci et al.   JOURNAL OF CLINICAL ONCOLOGY

The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas

(2015) R. Nussinov et al.   MOLECULAR CANCER RESEARCH

Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer

(2015) Kaiyu Yuan et al.   Oncotarget

Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling

(2015) Neha Woods et al.   Oncotarget

ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells

(2013) Chunning Zheng et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission

(2012) D. van der Hoeven et al.   MOLECULAR AND CELLULAR BIOLOGY

Calmodulin Mediates Fas-induced FADD-independent Survival Signaling in Pancreatic Cancer Cells via Activation of Src-Extracellular Signal-regulated Kinase (ERK)

(2011) Kaiyu Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function

(2010) B Alvarez-Moya et al.   ONCOGENE

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines

(2009) Ling-Yen Chiu et al.   TOXICOLOGY LETTERS

The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH